Log In
BCIQ
Print this Print this
 

VM200

  Manage Alerts
Collapse Summary General Information
Company Case Western Reserve University
DescriptionSmall molecule that neutralizes toxic chemicals produced during the visual cycle and prevents retinal damage and cell death
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat Sjogrren Larson Syndrome; Treat Stargardt disease; Treat succininc semi-aldheyde dehydrogenase deficiency
Regulatory Designation
PartnerVision Medicines Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/09/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today